Helvacioglu A, Yeoman R R, Hazelton J M, Aksel S
Department of Obstetrics and Gynecology, University of South Alabama, Mobile 36688.
J Reprod Med. 1993 Nov;38(11):864-70.
The results of long-acting, injectible gonadotropin releasing hormone agonist (GnRH-a) and placebo treatment of severe premenstrual syndrome (PMS) patients with regular menstrual cycles and without known psychiatric disorders are reported. Diagnosis was made according to the Menstrual Symptom Questionnaire and Menstrual Symptom Diary scores. In a placebo-controlled, crossover study, 12 subjects were given either normal saline or depot leuprolide acetate (7.5 mg) every 30 days, starting with the onset of menses. Each subject received the same agent twice before switching to the other and did not known which agent was given. A significant decrease in PMS symptoms was reported by all subjects in both treatment regimens. Biweekly venous blood sampling showed significant elevations of beta-endorphin levels and suppression of gonadotropin concentrations in subjects receiving depot leuprolide treatment. Short-term treatment of severe PMS with an injectible, long-acting GnRH-a may not treat the disease more than do saline injections in a group of women selected by certain criteria.
本文报告了长效注射用促性腺激素释放激素激动剂（GnRH-a）和安慰剂治疗月经周期规律且无已知精神疾病的重度经前综合征（PMS）患者的结果。诊断依据月经症状问卷和月经症状日记评分做出。在一项安慰剂对照的交叉研究中，12名受试者从月经开始时起，每30天接受一次生理盐水或醋酸亮丙瑞林长效注射剂（7.5毫克）。每个受试者在换用另一种药物之前，均接受相同药物治疗两次，且不知道所给予的是哪种药物。两种治疗方案中的所有受试者均报告经前综合征症状显著减轻。接受醋酸亮丙瑞林长效注射剂治疗的受试者每两周进行的静脉血采样显示，β-内啡肽水平显著升高，促性腺激素浓度受到抑制。在一组经特定标准挑选出的女性中，用注射用长效GnRH-a对重度经前综合征进行短期治疗，其治疗效果可能并不优于注射生理盐水。
